Holen Sie sich die Stockscreener-App
7.80
9.57%
-0.825
Handel nachbörslich:
8.70
0.90
+11.54%
Schlusskurs vom Vortag:
$8.625
Offen:
$8.53
24-Stunden-Volumen:
122.38K
Relative Volume:
5.95
Marktkapitalisierung:
$5.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.82M
KGV:
-0.2501
EPS:
-31.1883
Netto-Cashflow:
$-14.79M
1W Leistung:
-12.95%
1M Leistung:
-32.00%
6M Leistung:
-23.00%
1J Leistung:
-75.40%
1-Tages-Spanne:
$7.80
$9.00
1-Wochen-Bereich:
$7.80
$9.09
52-Wochen-Spanne:
$7.01
$35.17
Envveno Medical Corp Stock (NVNO) Company Profile
Firmenname
Envveno Medical Corp
Sektor
Branche
Telefon
949-261-2900
Adresse
70 DOPPLER, IRVINE
Compare NVNO vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
7.80 | 6.02M | 0 | -18.82M | -14.79M | -31.19 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp Aktie (NVNO) Neueste Nachrichten
Envveno Medical Stock Price Forecast. Should You Buy NVNO? - StockInvest.us
enVVeno Medical Corp (NASDAQ: NVNO) Activist Ownership Drops to Zero Following Complete Stake Sale - Kalkine Media
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series - Yahoo Finance
About 3 million people in the U.S. are estimated to live with severe deep-vein disease. enVVeno's new videos explain it. - Stock Titan
Enveno medical director Francis Duhay sells $123 in shares By Investing.com - Investing.com Australia
Two major holders fully exit enVVeno Medical Corp (NVNO) - Stock Titan
Enveno medical director Francis Duhay sells $123 in shares - Investing.com
Director Francis Duhay Sells 11 Shares of enVVeno Medical Corp (NVNO) - GuruFocus
enVVeno Medical (NVNO) director logs small preset stock sale - Stock Titan
Director at enVVeno (NASDAQ: NVNO) plans sale of 11 shares - Stock Titan
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - ACCESS Newswire
A medical-device CEO's presentation is now online ahead of New York meetings - Stock Titan
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - ACCESS Newswire
EnVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - marketscreener.com
enVVeno Medical files prospectus to offer securities for up to $100 million - scanx.trade
enVVeno Medical (NASDAQ: NVNO) readies $100M in potential securities sales - Stock Titan
Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants - Stock Titan
NVNO Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 8.54%Estimate Uncertainty - Vinanet
NVNO Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development CostsEPS Consistency Score - vinanet.vn
enVVeno study shows $32,000 savings per patient for venous valve therapy - scanx.trade
enVVeno Medical (NVNO) Highlights Cost-Effectiveness of VenoValve Amid Challenging Valuation Metrics - GuruFocus
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - ACCESS Newswire
enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient - Stock Titan
enVVeno cites Journal of Vascular Surgery study showing venous valve therapy saves more than $32,000 per patient over five years - Bitget
EnVVeno Moves Toward U.S. Pivotal Trial - Orange County Business Journal
enVVeno Medical receives FDA approval for pivotal trial By Investing.com - Investing.com Nigeria
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve - Weatherford Democrat
FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO) - Stock Titan
NVNO Q2'26 Earnings: EPS estimate is (4.69) USD - TradingView
enVVeno Medical Corp (NVNO) Cash Flow - TradingKey
enVVeno Medical Corp expected to post a loss of $4.69 a shareEarnings Preview - TradingView
enVVeno Medical Corporation Revenue Breakdown – LS:A42085 - TradingView
enVVeno Medical Corp (NVNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
enVVeno Medical Corp (NVNO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
enVVeno Medical Corp (NVNO) Income Statement - TradingKey
NVNO|enVVeno Medical Corp|Price:10.390|Chg%:+0.160 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineEarnings Expansion Phase - dars.gov.et
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchZigzag Correction - dars.gov.et
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineBanking Earnings Report - po-news-eg.net
enVVeno Medical (NVNO) Holds Near Support Amid Minimal Price MovementMutual Fund Flow - careplusvn.com
NVNO Q3 2025 Earnings: Narrower Loss Than Expected as enVVeno Controls CostsDividend Cut Risk - vinanet.vn
NVNO Q3 2025 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineEarnings Manipulation Risk - dars.gov.et
NVNO Q3 2025 Earnings: Narrower-than-Expected Loss Despite Stock PullbackOne-Time Gain Impact - vinanet.vn
EnVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor What This Means Segment - marketscreener.com
enVVeno Medical Updates Investors With New Presentation - The Globe and Mail
NVNO Q3 2025 Earnings: Smaller-Than-Expected Loss Boosts Investor SentimentManagement Tone Analysis - vinanet.vn
enVVeno Medical highlights newly issued U.S. patent - TipRanks
enVVeno Medical (NVNO) Secures U.S. Patent and Advances FDA Tria - GuruFocus
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment - ACCESS Newswire
Finanzdaten der Envveno Medical Corp-Aktie (NVNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):